id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2026-P-6538-0003,FDA,FDA-2026-P-6538,"Determination That NAMENDA (Memantine Hydrochloride) Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness",Notice,Determinations,2026-09-01T04:00:00Z,2026,9,2026-09-01T04:00:00Z,,2026-09-01T17:17:13Z,2026-17812,0,0,09000064b94b119a
FDA-2026-P-6538-0004,FDA,FDA-2026-P-6538,Final Response Letter,Other,Response(s),2026-09-01T04:00:00Z,2026,9,2026-09-01T04:00:00Z,,2026-09-01T22:09:59Z,,0,0,09000064b94ba5b8
FDA-2026-P-6538-0001,FDA,FDA-2026-P-6538,Citizen Petition from Newcastle Bioscience LLC,Other,Citizen Petition,2026-06-08T04:00:00Z,2026,6,2026-06-08T04:00:00Z,,2026-09-01T21:14:35Z,,0,0,09000064b931c7e8
FDA-2026-P-6538-0002,FDA,FDA-2026-P-6538,Acknowledgement Letter from FDA DMB to Newcastle Bioscience LLC,Other,Acknowledgement Letter/Receipt,2026-06-08T04:00:00Z,2026,6,2026-06-08T04:00:00Z,,2026-06-08T23:18:08Z,,0,0,09000064b931c7eb